Dynamic Technology Lab Private Ltd Boosts Stake in Repligen Corporation $RGEN

Dynamic Technology Lab Private Ltd grew its position in shares of Repligen Corporation (NASDAQ:RGEN) by 77.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,294 shares of the biotechnology company’s stock after acquiring an additional 7,086 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Repligen were worth $2,027,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Twin Tree Management LP purchased a new stake in shares of Repligen during the 1st quarter worth about $29,000. Hantz Financial Services Inc. raised its holdings in Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 293 shares during the period. Signaturefd LLC raised its holdings in Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 128 shares during the period. Center for Financial Planning Inc. lifted its position in Repligen by 34.2% during the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 126 shares in the last quarter. Finally, AlphaQuest LLC purchased a new stake in Repligen during the second quarter worth approximately $104,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Performance

Repligen stock opened at $155.08 on Thursday. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The company has a market capitalization of $8.73 billion, a price-to-earnings ratio of 7,757.88, a price-to-earnings-growth ratio of 3.32 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The firm’s fifty day moving average price is $142.99 and its 200 day moving average price is $129.99.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The company had revenue of $188.81 million during the quarter, compared to analysts’ expectations of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The firm’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, research analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on RGEN. Hsbc Global Res raised shares of Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Tuesday, September 2nd. Jefferies Financial Group set a $160.00 price objective on Repligen and gave the company a “hold” rating in a research report on Tuesday, October 28th. HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Repligen in a research report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $173.85.

Insider Transactions at Repligen

In other Repligen news, COO James Bylund sold 2,191 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the transaction, the chief operating officer directly owned 21,520 shares of the company’s stock, valued at $3,254,039.20. This represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Anthony Hunt sold 25,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $156.88, for a total value of $3,922,000.00. Following the transaction, the director owned 100,743 shares of the company’s stock, valued at approximately $15,804,561.84. This trade represents a 19.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 49,382 shares of company stock valued at $7,676,802 in the last three months. 1.20% of the stock is currently owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.